Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
64%
Hematopoietic Cell Transplantation
45%
Natural Killer Cells
41%
Transplantation
35%
Unrelated Donor
29%
Acute Myeloid Leukemia
27%
Confidence Interval
25%
Marrow Transplantation
24%
Umbilical Cord Blood
22%
T Cells
22%
Bone Marrow Transplantation
21%
Hematopoietic Stem Cell Transplantation
20%
Overall Survival
18%
Umbilical Cord Blood Transplantation
16%
Reduced-intensity Conditioning
15%
Bone Marrow
14%
Treg
13%
Cell Therapy
13%
Regulatory T Cells
13%
Induced Pluripotent Stem Cells (iPSCs)
12%
Hematopoietic Stem Cells
12%
Acute Lymphoblastic Leukemia
11%
Pediatric
11%
Clinical Trials
11%
Sickle Cell Disease
11%
Acute Leukemia
11%
Chemotherapy
10%
Hazard Ratio
10%
Engraftment
10%
Transplant Outcomes
10%
Epidermolysis Bullosa
10%
Fanconi Anemia
9%
Myelodysplastic Syndrome
9%
Non-relapse Mortality
9%
Allogeneic Transplantation
9%
Killer Cell Immunoglobulin-like Receptor
9%
Hematopoietic Cell Transplant
9%
Hematological Malignancies
9%
Photosystem II
9%
Leukemia
9%
Tumor
9%
Children's Oncology Group
8%
Risk Factors
8%
Pretransplant
8%
HLA Matching
8%
Myeloablative Conditioning
8%
Marrow
8%
Interleukin-15 (IL-15)
8%
Allogeneic
8%
Unrelated Donor Transplantation
8%
Survivors
8%
Interleukin-2
8%
High Risk
8%
Clinical Outcomes
7%
Mesenchymal Stromal Cells
7%
Allogeneic Bone Marrow Transplantation
7%
Pediatric Patients
7%
Stem Cell-derived
7%
Electronic Health Records
7%
Myeloablative
7%
Lymphoma
7%
Cyclophosphamide
7%
Relative Risk
7%
First Complete Remission
7%
Transfusion
6%
Tacrolimus
6%
HLA-matched Donor
6%
Critically Ill children
6%
Relapsed or Refractory
6%
COVID-19
6%
Cytomegalovirus
6%
Peripheral Blood
6%
Graft-versus-leukemia Effect
6%
Embryonic Stem Cells
6%
Progression-free Survival
6%
Inflammation
6%
B Cells
6%
Myogenic Progenitors
6%
Conditioning Regimen
6%
Total Body Irradiation
6%
Older Adults
6%
Leukemia Patients
6%
Stem Cells
6%
Chronic Myeloid Leukemia
6%
Disease-free Survival
6%
Mouse Model
6%
United States
6%
Phase II Trial
6%
Fludarabine
6%
Ovarian Cancer
5%
Chimeric Antigen Receptor T Cells (CAR-T)
5%
Endothelial Cells
5%
T Cell Activation
5%
Stem Cell Transplantation
5%
CD8+ T Cells
5%
Adrenoleukodystrophy
5%
Hematopoietic Cells
5%
Multiple Myeloma
5%
Treatment-related Mortality
5%
Immunology and Microbiology
Hematopoietic Cell
72%
Graft-Versus-Host Disease
56%
Cell Transplantation
55%
Natural Killer Cell
42%
T Cell
37%
Umbilical Cord Blood
31%
Chronic Graft Versus Host Disease
29%
Acute Graft Versus Host Disease
27%
Regulatory T Cell
26%
Conditioning
25%
Infection
21%
Myeloid
19%
Hematopoietic Stem Cell Transplantation
17%
Cord Blood Stem Cell Transplantation
16%
Overall Survival
14%
Bone Marrow Transplantation
13%
Allograft
13%
B Cell
12%
In Vitro
11%
Engraftment
11%
Stem Cell
10%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Immunotherapy
9%
Cytokine
9%
Cyclophosphamide
8%
Mesenchymal Stem Cell
8%
Interleukin 2
8%
Cytomegalovirus
7%
Lineages
7%
Cell Function
7%
Neutrophil
7%
T-Helper Cell
6%
Cytotoxic T-Cell
6%
Platelet
6%
Tacrolimus
6%
Killer-Cell Immunoglobulin-Like Receptor
6%
Allele
6%
Interleukin 15
5%
Disease Free Survival
5%
Human Leukocyte Antigen
5%
CD34
5%
Blood Plasma
5%
CD4
5%
Medicine and Dentistry
Hematopoietic Cell
72%
Cell Transplantation
56%
Diseases
31%
Graft Versus Host Reaction
30%
Cord Blood
22%
Chronic Graft Versus Host Disease
22%
Acute Myeloid Leukemia
22%
Hematopoietic Stem Cell Transplantation
20%
Overall Survival
19%
T Cell
18%
Bone Marrow Transplantation
18%
Pediatrics
17%
Natural Killer Cell
16%
Allograft
13%
Acute Graft Versus Host Disease
13%
Cell Therapy
13%
Acute Lymphoblastic Leukemia
12%
Clinical Trial
12%
Leukemia
11%
Infection
11%
Hazard Ratio
10%
Myelodysplastic Syndrome
9%
Reduced Intensity Conditioning
9%
Malignant Neoplasm
9%
Cord Blood Stem Cell Transplantation
9%
Acute Leukemia
9%
Oncology
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Neoplasm
9%
Sickle-Cell Disease
9%
Conditioning
9%
Stem Cell
8%
Hurler Syndrome
7%
Platelet
7%
In Vitro
7%
Regulatory T Cell
7%
Fanconi Anemia
7%
Engraftment
7%
Ovarian Cancer
6%
Immunotherapy
6%
Lung
6%
Hematologic Malignancy
6%
B Cell
6%
Progression Free Survival
6%
Epidermolysis Bullosa Dystrophica
6%
Mesenchymal Stem Cell
5%
Cancer
5%
Biological Marker
5%
Induced Pluripotent Stem Cell
5%
Infusion
5%
COVID-19
5%
Whole Body Radiation
5%
Multiple Myeloma
5%
Cyclophosphamide
5%
Disease Free Survival
5%